Abstract
An 80-year-old man with an approximately 3-cm mass in the right submandibular region presented to our institution. Magnetic resonance imaging revealed enlarged lymph nodes (LNs) in the right neck, and fluorine-18-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) indicated positive FDG accumulation in the right neck LNs only. Excisional biopsy was performed for suspected malignant lymphoma, and the biopsy revealed melanoma. Close examination of the skin, nasal cavity, oral pharyngeal and laryngeal cavities, and gastrointestinal tract were performed. No primary tumor was detected by these examinations, and the patient was diagnosed with cervical LN metastasis from melanoma of unknown primary of clinical stage T0N3bM0 stage IIIC. The patient refused cervical neck dissection because of his age and comorbidity of Alzheimer’s disease and instead opted for proton beam therapy (PBT) at a total dose of 69 Gy (relative biological effectiveness) in 23 fractions. He did not receive any systemic therapy. The enlarged LNs shrunk slowly, and FDG PET/CT at 1 year after PBT showed that the right submandibular LN had shrunk from 27 to 7 mm in length, and there was no significant FDG accumulation. At 6 years and 4 months after PBT, the patient is alive without any recurrence.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Melanoma of known primary (MKP) develops on the skin, eyes, and mucous membranes, while melanoma of unknown primary (MUP) is defined as melanoma discovered in subcutaneous tissue, lymph nodes (LNs), or visceral organs without a primary site [1]. MUP is rare, accounting for approximately 3% of all melanomas, and 40–60% of MUP cases involve the LNs, including the axilla (50%) and cervical (30%) LNs [2]. MUP presents at a median age of 40–50 years and exhibits a male preponderance (male:female ratio ~ 2:1) [2].
The standard definitive treatment for melanoma of the head and neck is surgery, radiotherapy including particle therapy, or surgery followed by radiotherapy; the prognosis is poor regardless of the treatment. On the other hand, the standard definitive treatment for MUP is surgery, and MUP reportedly has a better prognosis than that of MKP, suggesting that these two diseases potentially have different characteristics and treatment outcomes [3]. Because MUP is rare, outcomes after treatments other than surgery have hardly been reported, including in case reports. We report an octogenarian patient with cervical LN metastasis from MUP who refused surgery due to his advanced age and comorbidity of Alzheimer’s disease and who was successfully treated with proton beam therapy (PBT).
Case report
An 80-year-old man with a 3-cm tumor in the right submandibular region presented to our institution. At the first visit, his Eastern Cooperative Oncology Group performance status was 0. Magnetic resonance imaging of the neck revealed a LN of 2.7 cm in maximum diameter in the right submandibular region, and six LNs measured approximately 1.0 cm in the right upper jugular region (Fig. 1a). These LNs showed low signal intensity on T1-weighted images, high signal intensity on diffusion-weighted images, and low apparent diffusion coefficient values. Fluorine-18-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) indicated significant positive FDG accumulation in the right neck LNs only; consequently, malignant lymphoma was suspected. A maximum intensity projection PET image is shown in Fig. 1b. Excisional biopsy was performed, and the tumor was grayish-white macroscopically. Histological evaluation revealed a sheet-like growth of strongly atypical tumor cells with extensive necrosis and melanin granules in tissues stained with hematoxylin–eosin (Fig. 2). Immunohistochemistry showed positive staining for vimentin, HMB45, S-100, and MART1. Based on these findings, the tumor was diagnosed as malignant melanoma. Programmed death ligand 1 and BRAF mutations were not assessed at the time of diagnosis.
The search for the primary site of the melanoma was performed by a dermatologist, gastroenterologist, and otorhinolaryngologist, but no primary site was obvious in the external or middle ear, nasal cavity, oral pharyngeal and laryngeal cavities, esophagus, stomach, duodenum, or cutaneous region. Thus, the patient was diagnosed with cervical LN metastasis from MUP of clinical stage T0N3bM0 stage IIIC according to the 8th edition of the American Joint Committee on Cancer staging manual. Although neck dissection was recommended as the primary treatment option, the patient and his family refused surgery due to his advanced age and comorbidity of Alzheimer’s disease. Systemic therapies, such as programmed death 1 antibody and BRAF/MEK inhibitors, are a treatment option for inoperable patients with stage IIIC melanoma; however, these drugs were not covered by national health insurance yet, and the patient opted for PBT instead of chemotherapy using dacarbazine. Passive-scattering PBT was delivered using anterior and right lateral beams. A dose of 3 Gy (relative biological effectiveness [RBE]) per fraction, 5 times per week, for a total dose of 69 Gy (RBE), was prescribed. The radiation field encompassed the clinically positive LNs and surrounding enlarged LNs at level Ib, II, and III in the right neck (Fig. 3). After delivering a dose of 60 Gy (RBE), the treatment plan was slightly modified to reduce the dose to the pharynx. The maximum dose, as the equivalent dose in 2 Gy fractions (EQD2), to the pharynx was 71.7 Gy (RBE). PBT was completed without interruption in an outpatient setting, and the only acute adverse events experienced were grade 3 dermatitis and grade 2 mucositis according to the Common Terminology Criteria for Adverse Events, version 5.
Serial FDG PET/CT images before and after PBT are shown in Fig. 4. At 3 months after PBT initiation, FDG PET/CT indicated that the tumor diameter had shrunk from 2.7 to 2.5 cm, but the FDG accumulation had not decreased. However, at 6 months, the tumor diameter had shrunk further to 1.3 cm, and FDG accumulation had diminished; the LNs in the cervical area had also shrunk. At 12 months, the tumor diameter was further reduced to 0.7 cm, and FDG accumulation was no longer apparent. Thereafter, PET/CT or enhanced CT was performed every 6 months, and no local recurrence or distant metastasis was observed at 6 years and 4 months after PBT. No late adverse event of grade 2 or higher was seen.
Discussion
The mechanism and pathogenesis of MUP are considered to be largely related to the spontaneous regression of melanoma from a known primary site [4]. The spontaneous regression of melanoma likely involves both cell-mediated and humoral immune mechanisms, and melanoma-specific antibodies are highly prevalent in the serum of MUP patients [5]. It has been reported that an increased number of tumor-infiltrating lymphocytes is a favorable prognostic factor for MUP [6]. Other factors that may induce the development of MUP include ectopic melanocytes that reach the LNs via the dermis and lymphatic vessels [7].
Dasgupta et al. proposed the following exclusion criteria for the diagnosis of MUP to avoid missing the primary site: (i) evidence of previous orbital exenteration or enucleation; (ii) evidence of a previous skin excision, electrodessication, cauterization, or other surgical manipulation of a mole, freckle, birthmark, paronychia, or skin blemish; (iii) evidence of metastatic melanoma in a draining lymph node and a scar in the skin area supplying the lymph node basin; and (iv) lack of a thorough physical examination, including ophthalmologic, anal, and genital exams [1]. However, fewer than 20% of reported MUP cases meet these exclusion criteria, and there is still insufficient consensus on the detection of the primary site [2]. In this case, although examination of the perineal region and eyes was insufficient, we considered the diagnosis of MUP to be adequate because the patient has been followed up with a physical examination, PET, and enhanced CT for more than 6 years without identification of a primary tumor since PBT.
Surgical management is a standard treatment for regional metastasis from MUP. In a matched-pair analysis of stage III patients who were managed with regional lymphadenectomy for nodal metastasis from MUP or MKP, the 5-year overall survival (OS) rate was significantly higher for MUP patients than MKP patients (58% vs. 40% p = 0.0006) [8]. Moreover, local control improved the 5-year OS rate in patients with lymph node metastasis from MUP (54% in the radical neck dissection group vs. 26% in the no dissection group), and surgery not only reduced the tumor volume but also stimulated anti-tumor immunity by downregulating immunosuppression toward the tumor, suggesting the importance of definitive local treatment for lymph node metastasis from MUP [1, 9]. In our case, radical neck dissection was not performed, but local therapy with PBT achieved good local control, which probably increased the survival of the patient.
Melanoma is radioresistant. Overgaard et al. analyzed 204 melanomas treated with fractionated radiotherapy assuming a low α/β value of 2.5 based on the linear–quadratic model, which describes the relationship between cell survival and the delivered dose of fractionated radiotherapy; this suggests that hypofractionated radiotherapy is better than conventional fractionated radiotherapy at improving local control [10]. That study also showed that a high total biologically effective dose (BED), which was calculated based on the linear–quadratic model with an α/β value set to 2.5, was associated with better tumor response, and the BED for a 50% complete response was estimated to be 125 Gy. In fact, in a multi-institutional retrospective study of radiotherapy for mucosal melanoma of the head and neck in Japan, Wada et al. reported that a hypofractionated radiotherapy dose ≥ 3 Gy per fraction and a high BED ≥ 118 Gy resulted in significantly better local control and OS rates [11]. In the present case, hypofractionation of 3 Gy (RBE) per fraction and a high total dose of 69 Gy (RBE), which was a BED of 151.8 Gy (RBE), resulted in good local control. Meanwhile, proton beams reduced the irradiated doses and volumes in the pharynx, and the treatment was well tolerated despite the patient’s age, with no acute or late mucositis of grade 3 or greater observed.
Today, with the widespread use of various high-precision radiotherapy techniques, an increasing number of patients are receiving definitive radiotherapy via stereotactic body radiotherapy or intensity-modulated radiotherapy using X-rays [12, 13]; however, particle therapy is preferable because it can deliver high doses while reducing the doses to surrounding organs [14]. In Japan, particle therapy for melanoma of the head and neck is covered by national health insurance, and it could be an effective treatment option for melanoma in patients who are not candidates for surgery or who refuse surgery.
In conclusion, we report a case of long-term survival after definitive PBT of cervical lymph node metastasis from MUP. Local control of MUP affects the survival rate, and high-dose hypofractionated radiotherapy could be an option for inoperable patients.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Dasgupta T, Bowden L, Berg JW (1963) Malignant melanoma of unknown primary origin. Surg Gynecol Obstet 117:341–345
Kamposioras K, Pentheroudakis G, Pectasides D et al (2011) Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 78:112–126
Bae JM, Choi YY, Kim DS et al (2015) Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 72:59–70
Savoia P, Fava P, Osella-Abate S et al (2010) Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Centre. Melanoma Res 20:227–232
Litvak DA, Gupta RK, Yee R et al (2004) Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg 198:27–35
Haanen JBAG, Baars A, Gomez R et al (2006) Melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55:451–458
Bankar S, Patkar S, Desai S et al (2015) Unusual presentation of melanoma of unknown primary origin: a case report and review of literature. J Cancer Res Ther 11:1025
Lee CC, Faries MB, Wanek LA et al (2008) Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 26:535–541
Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83:1664–1678
Overgaard J, Overgaard M, Hansen PV et al (1986) Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 5:183–192
Wada H, Nemoto K, Ogawa Y et al (2004) A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys 59:495–500
Malik NH, Kim MS, Chen H et al (2020) Stereotactic radiation therapy for de novo head and neck cancers: a systematic review and meta-analysis. Adv Radiat Oncol 6:100628
Hawkins PG, Lee JY, Mao Y et al (2018) Sparing all salivary glands with IMRT for head and neck cancer: longitudinal study of patient-reported xerostomia and head-and-neck quality of life. Radiother Oncol 126:68–74
Leeman JE, Romesser PB, Zhou Y et al (2017) Proton therapy for head and neck cancer: expanding the therapeutic window. Lancet Oncol 18:e254–e265
Acknowledgements
The authors would like to thank JAM Post Inc. for English language editing.
Funding
This study received no financial support/funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest regarding this manuscript.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Informed consent
Written informed consent was obtained from the patient’s family for publication of this case report and any accompanying images.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Nakamura, M., Ohnishi, K., Uchida, F. et al. Proton beam therapy for cervical lymph node metastasis in an octogenarian with melanoma of unknown primary: a case report. Int Canc Conf J 12, 160–165 (2023). https://doi.org/10.1007/s13691-023-00597-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-023-00597-8